Investigation of Debio 025, a cyclophilin inhibitor, in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy.

@article{Reutenauer2008InvestigationOD,
  title={Investigation of Debio 025, a cyclophilin inhibitor, in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy.},
  author={J Reutenauer and Olivier M. Dorchies and Oph{\'e}lie Patthey-Vuadens and Gr{\'e}goire Vuagniaux and Urs T. Ruegg},
  journal={British journal of pharmacology},
  year={2008},
  volume={155 4},
  pages={574-84}
}
BACKGROUND AND PURPOSE Duchenne muscular dystrophy (DMD) is a severe muscle wasting disorder caused by the absence of the cytoskeletal protein dystrophin. This leads to muscle cell death accompanied by chronic inflammation. Cyclosporin A (CsA) is a powerful immunosuppressive drug, which has been proposed for DMD treatment. CsA also directly regulates the mitochondrial permeability transition pore (mPTP), which participates in cell death pathways through the inhibition of cyclophilin D. Here, we… CONTINUE READING
34 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 34 extracted citations

Similar Papers

Loading similar papers…